<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">34048130</PMID><DateCompleted><Year>2021</Year><Month>10</Month><Day>18</Day></DateCompleted><DateRevised><Year>2022</Year><Month>12</Month><Day>07</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1468-1331</ISSN><JournalIssue CitedMedium="Internet"><Volume>28</Volume><Issue>9</Issue><PubDate><Year>2021</Year><Month>Sep</Month></PubDate></JournalIssue><Title>European journal of neurology</Title><ISOAbbreviation>Eur J Neurol</ISOAbbreviation></Journal><ArticleTitle>Trends in the clinical features of amyotrophic lateral sclerosis: A 14-year Chinese cohort study.</ArticleTitle><Pagination><StartPage>2893</StartPage><EndPage>2900</EndPage><MedlinePgn>2893-2900</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1111/ene.14943</ELocationID><Abstract><AbstractText Label="BACKGROUND AND PURPOSE">The aim was to determine the transitional patterns in the clinical characteristics, treatments and comorbidities in amyotrophic lateral sclerosis (ALS) patients over the past 14&#xa0;years using data from a large clinical cohort in mainland China.</AbstractText><AbstractText Label="METHODS">Sporadic ALS patients who visited the Peking University Third Hospital from January 2005 to December 2018 were included in this study. The 14&#xa0;years were divided into three periods, and changes in the baseline characteristics of the participants were analyzed at 5-year intervals.</AbstractText><AbstractText Label="RESULTS">In total, 3410 patients with sporadic ALS were recruited: 2181 were men and 1229 were women. The proportion of patients with bulbar-onset ALS increased from 13.0% in 2005-2009 to 19.5% in 2015-2018 (p&#xa0;&lt;&#xa0;0.001). The mean (standard deviation) age at onset increased from 49.5 (11.4) years in 2005-2009 to 53.0 (11.0) years in 2015-2018 (p&#xa0;&lt;&#xa0;0.001). ALS patients with diabetes or hypertension showed a delay in ALS onset, and the delay was even more apparent when the patients had both comorbidities. The proportion of riluzole users in 2015-2018 was approximately 2.5-fold of that in 2005-2009 (p&#xa0;&lt;&#xa0;0.001).</AbstractText><AbstractText Label="CONCLUSIONS">In the context of a lack of clinical data on ALS in mainland China, this study evaluated a large cohort of patients diagnosed over a 14-year period. The age at onset and percentage of patients who used riluzole both increased over the study period. Additionally, it was found that patients with comorbidities such as diabetes and hypertension had a delayed age of ALS onset.</AbstractText><CopyrightInformation>&#xa9; 2021 European Academy of Neurology.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Chen</LastName><ForeName>Lu</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Department of Neurology, Peking University Third Hospital, Beijing, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Xu</LastName><ForeName>Lu</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Department of Epidemiology and Biostatistics, School of Public Health, Peking University, Beijing, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tang</LastName><ForeName>Lu</ForeName><Initials>L</Initials><Identifier Source="ORCID">0000-0002-3589-6287</Identifier><AffiliationInfo><Affiliation>Department of Neurology, Peking University Third Hospital, Beijing, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Xia</LastName><ForeName>Kailin</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Department of Neurology, Peking University Third Hospital, Beijing, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tian</LastName><ForeName>Danyang</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Department of Neurology, Peking University Third Hospital, Beijing, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhang</LastName><ForeName>Gan</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Department of Neurology, Peking University Third Hospital, Beijing, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wang</LastName><ForeName>Yajun</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Department of Neurology, Peking University Third Hospital, Beijing, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yu</LastName><ForeName>Zhou</ForeName><Initials>Z</Initials><AffiliationInfo><Affiliation>Department of Neurology, Peking University Third Hospital, Beijing, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ma</LastName><ForeName>Jingyue</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Neurology, Peking University Third Hospital, Beijing, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhang</LastName><ForeName>Yixuan</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Department of Neurology, Peking University Third Hospital, Beijing, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wang</LastName><ForeName>Fan</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Department of Neurology, Peking University Third Hospital, Beijing, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sun</LastName><ForeName>Can</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Department of Neurology, Peking University Third Hospital, Beijing, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhang</LastName><ForeName>Gaoqi</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Department of Neurology, Peking University Third Hospital, Beijing, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Fu</LastName><ForeName>Jiayu</ForeName><Initials>J</Initials><Identifier Source="ORCID">0000-0002-6838-582X</Identifier><AffiliationInfo><Affiliation>Department of Neurology, Peking University Third Hospital, Beijing, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Jiao</LastName><ForeName>Lin</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Department of Neurology, Peking University Third Hospital, Beijing, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yilihamu</LastName><ForeName>Mubalake</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Neurology, Peking University Third Hospital, Beijing, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wang</LastName><ForeName>Shengfeng</ForeName><Initials>S</Initials><Identifier Source="ORCID">0000-0001-9397-0409</Identifier><AffiliationInfo><Affiliation>Department of Epidemiology and Biostatistics, School of Public Health, Peking University, Beijing, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhan</LastName><ForeName>Siyan</ForeName><Initials>S</Initials><Identifier Source="ORCID">0000-0001-7252-5349</Identifier><AffiliationInfo><Affiliation>Department of Epidemiology and Biostatistics, School of Public Health, Peking University, Beijing, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Research Center of Clinical Epidemiology, Peking University Third Hospital, Beijing, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Center for Intelligent Public Health, Institute for Artificial Intelligence, Peking University, Beijing, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Fan</LastName><ForeName>Dongsheng</ForeName><Initials>D</Initials><Identifier Source="ORCID">0000-0002-6679-0864</Identifier><AffiliationInfo><Affiliation>Department of Neurology, Peking University Third Hospital, Beijing, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Key Laboratory for Neuroscience, National Health Commission/Ministry of Education, Peking University, Beijing, China.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2021</Year><Month>06</Month><Day>25</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Eur J Neurol</MedlineTA><NlmUniqueID>9506311</NlmUniqueID><ISSNLinking>1351-5101</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>7LJ087RS6F</RegistryNumber><NameOfSubstance UI="D019782">Riluzole</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000690" MajorTopicYN="Y">Amyotrophic Lateral Sclerosis</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D044466" MajorTopicYN="N">Asian People</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002681" MajorTopicYN="N" Type="Geographic">China</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015331" MajorTopicYN="N">Cohort Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D019782" MajorTopicYN="N">Riluzole</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">amyotrophic lateral sclerosis</Keyword><Keyword MajorTopicYN="N">clinical features</Keyword><Keyword MajorTopicYN="N">comorbidities</Keyword><Keyword MajorTopicYN="N">temporal trend</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="revised"><Year>2021</Year><Month>5</Month><Day>10</Day></PubMedPubDate><PubMedPubDate PubStatus="received"><Year>2021</Year><Month>4</Month><Day>2</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2021</Year><Month>5</Month><Day>19</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2021</Year><Month>5</Month><Day>29</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2021</Year><Month>10</Month><Day>21</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2021</Year><Month>5</Month><Day>28</Day><Hour>12</Hour><Minute>28</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">34048130</ArticleId><ArticleId IdType="doi">10.1111/ene.14943</ArticleId></ArticleIdList><ReferenceList><Title>REFERENCES</Title><Reference><Citation>Shahrizaila N, Sobue G, Kuwabara S, et al. Amyotrophic lateral sclerosis and motor neuron syndromes in Asia. J Neurol Neurosurg Psychiatry. 2016;87(8):821-830.</Citation></Reference><Reference><Citation>Collaborators GMND. Global, regional, and national burden of motor neuron diseases 1990-2016: a systematic analysis for the Global Burden of Disease Study 2016. Lancet Neurol. 2018;17(12):1083-1097.</Citation></Reference><Reference><Citation>Kurian KM, Forbes RB, Colville S, Swingler RJ. Cause of death and clinical grading criteria in a cohort of amyotrophic lateral sclerosis cases undergoing autopsy from the Scottish Motor Neurone Disease Register. J Neurol Neurosurg Psychiatry. 2009;80(1):84-87.</Citation></Reference><Reference><Citation>Nzwalo H, de Abreu D, Swash M, Pinto S, de Carvalho M. Delayed diagnosis in ALS: the problem continues. J Neurol Sci. 2014;343(1-2):173-175.</Citation></Reference><Reference><Citation>Chio A, Mora G, Calvo A, et al. Epidemiology of ALS in Italy: a 10-year prospective population-based study. Neurology. 2009;72(8):725-731.</Citation></Reference><Reference><Citation>Arthur KC, Calvo A, Price TR, Geiger JT, Chio A, Traynor BJ. Projected increase in amyotrophic lateral sclerosis from 2015 to 2040. Nat Commun. 2016;7:12408.</Citation></Reference><Reference><Citation>Georgoulopoulou E, Vinceti M, Bonvicini F, et al. Changing incidence and subtypes of ALS in Modena, Italy: a 10-years prospective study. Amyotroph Lateral Scler. 2011;12(6):451-457.</Citation></Reference><Reference><Citation>Chen L, Zhang B, Chen R, et al. Natural history and clinical features of sporadic amyotrophic lateral sclerosis in China. J Neurol Neurosurg Psychiatry. 2015;86(10):1075-1081.</Citation></Reference><Reference><Citation>Moglia C, Calvo A, Canosa A, et al. Influence of arterial hypertension, type 2 diabetes and cardiovascular risk factors on ALS outcome: a population-based study. Amyotroph Lateral Scler Frontotemporal Degener. 2017;18(7-8):590-597.</Citation></Reference><Reference><Citation>Tsai CP, Lee JK, Lee CT. Type II diabetes mellitus and the incidence of amyotrophic lateral sclerosis. J Neurol. 2019;266(9):2233-2243.</Citation></Reference><Reference><Citation>Zhang L, Chen L, Fan D. The protective role of pre-morbid type 2 diabetes in patients with amyotrophic lateral sclerosis: a center-based survey in China. Amyotroph Lateral Scler Frontotemporal Degener. 2020;21(3-4):209-215.</Citation></Reference><Reference><Citation>Mariosa D, Kamel F, Bellocco R, Ye W, Fang F. Association between diabetes and amyotrophic lateral sclerosis in Sweden. Eur J Neurol. 2015;22(11):1436-1442.</Citation></Reference><Reference><Citation>Kioumourtzoglou MA, Rotem RS, Seals RM, Gredal O, Hansen J, Weisskopf MG. Diabetes mellitus, obesity, and diagnosis of amyotrophic lateral sclerosis: a population-based study. JAMA Neurol. 2015;72(8):905-911.</Citation></Reference><Reference><Citation>Xiong X, Zhang Z, Ren J, et al. Impact of universal medical insurance system on the accessibility of medical service supply and affordability of patients in China. PLoS One. 2018;13(3):e0193273.</Citation></Reference><Reference><Citation>Brooks BR, Miller RG, Swash M, Munsat TL. El Escorial revisited: revised criteria for the diagnosis of amyotrophic lateral sclerosis. Amyotroph Lateral Scler Other Motor Neuron Disord. 2000;1(5):293-299.</Citation></Reference><Reference><Citation>Wijesekera LC, Mathers S, Talman P, et al. Natural history and clinical features of the flail arm and flail leg ALS variants. Neurology. 2009;72(12):1087-1094.</Citation></Reference><Reference><Citation>Chen C, Lu FC. The guidelines for prevention and control of overweight and obesity in Chinese adults. Biomed Environ Sci. 2004;17(Suppl):1-36.</Citation></Reference><Reference><Citation>Govoni V, Della Coletta E, Cesnik E, Casetta I, Granieri E. Can the age at onset give a clue to the pathogenesis of ALS? Acta Neurol Belg. 2017;117(1):221-227.</Citation></Reference><Reference><Citation>Fong GC, Cheng TS, Lam K, et al. An epidemiological study of motor neuron disease in Hong Kong. Amyotroph Lateral Scler Other Motor Neuron Disord. 2005;6(3):164-168.</Citation></Reference><Reference><Citation>Kihira T, Yoshida S, Hironishi M, Miwa H, Okamato K, Kondo T. Changes in the incidence of amyotrophic lateral sclerosis in Wakayama, Japan. Amyotroph Lateral Scler Other Motor Neuron Disord. 2005;6(3):155-163.</Citation></Reference><Reference><Citation>Murphy M, Quinn S, Young J, Parkin P, Taylor B. Increasing incidence of ALS in Canterbury, New Zealand: a 22-year study. Neurology. 2008;71(23):1889-1895.</Citation></Reference><Reference><Citation>Kiernan MC, Talman P, Henderson RD, Harris R. Establishment of an Australian motor neurone disease registry. Med J Aust. 2006;184(7):367-368.</Citation></Reference><Reference><Citation>Xu L, Chen L, Wang S, et al. Incidence and prevalence of amyotrophic lateral sclerosis in urban China: a national population-based study. J Neurol Neurosurg Psychiatry. 2020;91(5):520-525.</Citation></Reference><Reference><Citation>Sabatelli M, Madia F, Conte A, et al. Natural history of young-adult amyotrophic lateral sclerosis. Neurology. 2008;71(12):876-881.</Citation></Reference><Reference><Citation>Kiernan MC, Vucic S, Cheah BC, et al. Amyotrophic lateral sclerosis. Lancet. 2011;377(9769):942-955.</Citation></Reference><Reference><Citation>Hardiman O, Al-Chalabi A, Brayne C, et al. The changing picture of amyotrophic lateral sclerosis: lessons from European registers. J Neurol Neurosurg Psychiatry. 2017;88(7):557-563.</Citation></Reference><Reference><Citation>Byrne S, Jordan I, Elamin M, Hardiman O. Age at onset of amyotrophic lateral sclerosis is proportional to life expectancy. Amyotroph Lateral Scler Frontotemporal Degener. 2013;14(7-8):604-607.</Citation></Reference><Reference><Citation>Average life expectancy of Chinese population. National Bureau of Statistics. http://wwwstatsgovcn/tjsj/. Accessed April 5, 2020; 2020.</Citation></Reference><Reference><Citation>Turner MR, Scaber J, Goodfellow JA, Lord ME, Marsden R, Talbot K. The diagnostic pathway and prognosis in bulbar-onset amyotrophic lateral sclerosis. J Neurol Sci. 2010;294(1-2):81-85.</Citation></Reference><Reference><Citation>Seelen M, van Doormaal PT, Visser AE, et al. Prior medical conditions and the risk of amyotrophic lateral sclerosis. J Neurol. 2014;261(10):1949-1956.</Citation></Reference><Reference><Citation>Dupuis L, Pradat PF, Ludolph AC, Loeffler JP. Energy metabolism in amyotrophic lateral sclerosis. Lancet Neurol. 2011;10(1):75-82.</Citation></Reference><Reference><Citation>D'Ovidio F, Rooney JPK, Visser AE, et al. Association between alcohol exposure and the risk of amyotrophic lateral sclerosis in the Euro-MOTOR study. J Neurol Neurosurg Psychiatry. 2019;90(1):11-19.</Citation></Reference><Reference><Citation>Lin FC, Tsai CP, Kuang-Wu Lee J, Wu MT, Tzu-Chi LC. Angiotensin-converting enzyme inhibitors and amyotrophic lateral sclerosis risk: a total population-based case-control study. JAMA Neurol. 2015;72(1):40-48.</Citation></Reference><Reference><Citation>Kaneb HM, Sharp PS, Rahmani-Kondori N, Wells DJ. Metformin treatment has no beneficial effect in a dose-response survival study in the SOD1(G93A) mouse model of ALS and is harmful in female mice. PLoS One. 2011;6(9):e24189.</Citation></Reference><Reference><Citation>Shibata N, Kawaguchi-Niida M, Yamamoto T, Toi S, Hirano A, Kobayashi M. Effects of the PPARgamma activator pioglitazone on p38 MAP kinase and IkappaBalpha in the spinal cord of a transgenic mouse model of amyotrophic lateral sclerosis. Neuropathology. 2008;28(4):387-398.</Citation></Reference><Reference><Citation>Sch&#xfc;tz B, Reimann J, Dumitrescu-Ozimek L, et al. The oral antidiabetic pioglitazone protects from neurodegeneration and amyotrophic lateral sclerosis-like symptoms in superoxide dismutase-G93A transgenic mice. J Neurosci. 2005;25(34):7805-7812.</Citation></Reference><Reference><Citation>Kiaei M, Kipiani K, Chen J, Calingasan NY, Beal MF. Peroxisome proliferator-activated receptor-gamma agonist extends survival in transgenic mouse model of amyotrophic lateral sclerosis. Exp Neurol. 2005;191(2):331-336.</Citation></Reference><Reference><Citation>Dupuis L, Dengler R, Heneka MT, et al. A randomized, double blind, placebo-controlled trial of pioglitazone in combination with riluzole in amyotrophic lateral sclerosis. PLoS One. 2012;7(6):e37885.</Citation></Reference><Reference><Citation>Abraham A, Drory VE. Influence of serum uric acid levels on prognosis and survival in amyotrophic lateral sclerosis: a meta-analysis. J Neurol. 2014;261(6):1133-1138.</Citation></Reference><Reference><Citation>Zheng Z, Guo X, Wei Q, et al. Serum uric acid level is associated with the prevalence but not with survival of amyotrophic lateral sclerosis in a Chinese population. Metab Brain Dis. 2014;29(3):771-775.</Citation></Reference><Reference><Citation>Lee SU, Ryu V, Soh M, et al. Changes in antipsychotic drug usage and factors affecting the use of typical drugs based on nationwide health insurance data in South Korea. BMJ Open. 2018;8(6):e020280.</Citation></Reference><Reference><Citation>Chen L, Liu X, Tang L, Zhang N, Fan D. Long-term use of riluzole could improve the prognosis of sporadic amyotrophic lateral sclerosis patients: a real-world cohort study in China. Front Aging Neurosci. 2016;8:246.</Citation></Reference><Reference><Citation>Zarei S, Carr K, Reiley L, et al. A comprehensive review of amyotrophic lateral sclerosis. Surg Neurol Int. 2015;6:171.</Citation></Reference><Reference><Citation>Gu Y. Dynamic adjustment of medical insurance catalogue for rare diseases to make orphan drugs no longer lonely. China's Strategic Emerg Industries. 2017;21:24-26.</Citation></Reference><Reference><Citation>Braga AC, Gromicho M, Pinto S, de Carvalho M, Henning F. A comparative study of South African and Portuguese amyotrophic lateral sclerosis cohorts. J Neurol Sci. 2020;414:116857.</Citation></Reference><Reference><Citation>Dorst J, Chen L, Rosenbohm A, et al. Prognostic factors in ALS: a comparison between Germany and China. J Neurology. 2019;266(6):1516-1525.</Citation></Reference><Reference><Citation>Hojer-Pedersen E, Christensen PB, Jensen NB. Incidence and prevalence of motor neuron disease in two Danish counties. Neuroepidemiology. 1989;8(3):151-159.</Citation></Reference><Reference><Citation>Zoccolella S, Beghi E, Palagano G, et al. Analysis of survival and prognostic factors in amyotrophic lateral sclerosis: a population based study. J Neurol Neurosurg Psychiatry. 2008;79(1):33-37.</Citation></Reference><Reference><Citation>Westeneng HJ, Debray TPA, Visser AE, et al. Prognosis for patients with amyotrophic lateral sclerosis: development and validation of a personalised prediction model. Lancet Neurol. 2018;17(5):423-433.</Citation></Reference><Reference><Citation>Luna J, Diagana M, Ait Aissa L, et al. Clinical features and prognosis of amyotrophic lateral sclerosis in Africa: the TROPALS study. J Neurol Neurosurg Psychiatry. 2019;90(1):20-29.</Citation></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>